Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

被引：27
|
作者：
Choughule, A. [1 ]
Sharma, R. [1 ,2 ]
Trivedi, V. [1 ,2 ]
Thavamani, A. [1 ,2 ]
Noronha, V. [1 ]
Joshi, A. [1 ]
Desai, S. [3 ]
Chandrani, P. [2 ]
Sundaram, P. [2 ]
Utture, S. [1 ]
Jambhekar, N. [3 ]
Gupta, S. [1 ]
Aich, J. [2 ]
Prabhash, K. [1 ]
Dutt, A. [2 ]
机构：
[1] Tata Mem Hosp, Tata Mem Ctr, Dept Med Oncol, Bombay 400012, Maharashtra, India
[2] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Navi Mumbai, India
[3] Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India
来源：
BRITISH JOURNAL OF CANCER | 2014年 / 111卷 / 11期
基金：
英国惠康基金;
关键词：
GROWTH-FACTOR-RECEPTOR; GEFITINIB; THERAPY; GENE; ERLOTINIB; SURVIVAL; FEATURES;
D O I：
10.1038/bjc.2014.401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2203 / 2204
页数：4
相关论文
共 50 条
  • [21] EGFR R521K predicts cetuximab response in KRAS wild-type patients
    不详
    PHARMACOGENOMICS, 2012, 13 (07) : 746 - 746
  • [22] EPIDERMAL GROWTH FACTORS TYROSINE-KINASE INHIBITORS (EGFR-TKI) EFFICACY IN NSCLC PATIENTS WITH HIGH POLYSOMY OF CHROMOSOME 7 AND EGFR/KRAS WILD TYPE TUMORS
    Toffalorio, F.
    Conforti, F.
    Spitaleri, G.
    Catania, C.
    Noberasco, C.
    Lazzari, C.
    Barberis, M.
    de Marinis, F.
    De Pas, T.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S44 - S44
  • [23] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR Wild-Type Lung Cancer: When There Is a Target, There Is a Targeted Drug
    Zhou, Fei
    Chen, Xiaoxia
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : 523 - U197
  • [24] KRAS wild-type status predicts response to cetuximab in metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (7): : 365 - 365
  • [25] Tyrosine-kinase Expression Predicts Response to Sunitinib in Breast Cancer
    Spanheimer, P. M.
    Kulak, M. V.
    Carr, J. C.
    Woodfield, G. W.
    De Andrade, J. P.
    Sugg, S. L.
    Weigel, R. J.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S11 - S11
  • [26] Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS
    Furugaki, Koh
    Iwai, Toshiki
    Shirane, Masatoshi
    Kondoh, Kumiko
    Moriya, Yoichiro
    Mori, Kazushige
    ONCOLOGY REPORTS, 2010, 24 (05) : 1141 - 1146
  • [27] EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells
    Han, Weidong
    Pan, Hongming
    Chen, Yan
    Sun, Jie
    Wang, Yanshan
    Li, Jing
    Ge, Weiting
    Feng, Lifeng
    Lin, Xiaoying
    Wang, Xiaojia
    Wang, Xian
    Jin, Hongchuan
    PLOS ONE, 2011, 6 (06):
  • [28] High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
    Wang, Fang
    Fu, Sha
    Shao, Qiong
    Zhou, Yan-Bin
    Zhang, Xiao
    Zhang, Xu
    Xue, Cong
    Lin, Jian-Guang
    Huang, Li-Xia
    Zhang, Li
    Zhang, Wei-Min
    Shao, Jian-Yong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [29] High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR
    Fang Wang
    Sha Fu
    Qiong Shao
    Yan-Bin Zhou
    Xiao Zhang
    Xu Zhang
    Cong Xue
    Jian-Guang Lin
    Li-Xia Huang
    Li Zhang
    Wei-Min Zhang
    Jian-Yong Shao
    Journal of Translational Medicine, 11
  • [30] Concurrent Thoracic Radiotherapy and Tyrosine Kinase Inhibitors for Wild-Type EGFR Patients with Locally Advanced Non-Small Cell Lung Cancer
    Zheng, Zhi S.
    Xia, Bing
    Xie, Rui F.
    Li, Xia D.
    Zhu, Jue
    Wu, Shi X.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S548 - S548
12345